| (Values in U.S. Thousands) | Nov, 2024 | Nov, 2023 | Nov, 2022 | Nov, 2021 | Nov, 2020 |
| Sales | 85,866 | 81,764 | 80,057 | 69,823 | 66,053 |
| Sales Growth | +5.02% | +2.13% | +14.66% | +5.71% | +4.49% |
| Net Income | -8,306 | -23,957 | -47,237 | -31,725 | -22,667 |
| Net Income Growth | +65.33% | +49.28% | -48.90% | -39.96% | -81.39% |
Theratechnologies (TH.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.
Fiscal Year End Date: 11/30